147 related articles for article (PubMed ID: 36810555)
1. Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin's Lymphoma.
Tan GF; Goh S; Chang EWY; Tan YH; Chiang J; Yang VS; Poon EYL; Somasundaram N; Bin Harunal Rashid MF; Tao M; Lim ST; Ong CK; Chan JY
Hematol Rep; 2023 Feb; 15(1):108-118. PubMed ID: 36810555
[TBL] [Abstract][Full Text] [Related]
2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.
Porrata LF; Ristow K; Colgan JP; Habermann TM; Witzig TE; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
Haematologica; 2012 Feb; 97(2):262-9. PubMed ID: 21993683
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of preoperative neutrophil-to-lymphocyte ratio in histological variants of non-muscle-invasive bladder cancer.
Li DX; Wang XM; Tang Y; Yang YB; Feng DC; Li A; Zhang FC; Bai YJ; Han P
Investig Clin Urol; 2021 Nov; 62(6):641-649. PubMed ID: 34729964
[TBL] [Abstract][Full Text] [Related]
5. [The prognostic significance of peripheral lymphocyte/monocyte ratio and PET-2 evaluation in adult Hodgkin's lymphoma].
Jia T; Zhu HY; Wang L; Liang JH; Cao L; Xia Y; Wu JZ; Wu W; Fan L; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):372-377. PubMed ID: 31207700
[No Abstract] [Full Text] [Related]
6. High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.
Jaime-Pérez JC; Gamboa-Alonso CM; Padilla-Medina JR; Jiménez-Castillo RA; Olguín-Ramírez LA; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D
Rev Bras Hematol Hemoter; 2017; 39(4):325-330. PubMed ID: 29150104
[TBL] [Abstract][Full Text] [Related]
7. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
9. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.
Liao Z; Ha CS; Vlachaki MT; Hagemeister F; Cabanillas F; Hess M; Tucker S; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):971-7. PubMed ID: 11429225
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and analysis of prognostic factors of 222 patients diagnosed with Hodgkin's lymphoma].
Hu YF; Huang YH; Luo W; Chen MX; Zhang J; Gou F
Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(48):3792-3796. PubMed ID: 31874516
[No Abstract] [Full Text] [Related]
12. Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.
Gotti M; Nicola M; Lucioni M; Fiaccadori V; Ferretti V; Sciarra R; Costanza M; Bono E; Molo S; Maffi A; Croci GA; Varettoni M; Frigeni M; Pascutto C; Arcaini L; Bonfichi M; Paulli M; Cazzola M
Hematol Oncol; 2017 Sep; 35(3):296-302. PubMed ID: 27060262
[TBL] [Abstract][Full Text] [Related]
13. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma.
Zhu YJ; Sun YL; Xia Y; Jiang WQ; Huang JJ; Huang HQ; Lin TY; Guan ZZ; Li ZM
Med Oncol; 2012 Jun; 29(2):1127-33. PubMed ID: 21390515
[TBL] [Abstract][Full Text] [Related]
15. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer.
Mercier J; Voutsadakis IA
J Gastrointest Cancer; 2019 Sep; 50(3):493-506. PubMed ID: 29704170
[TBL] [Abstract][Full Text] [Related]
17. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of clinical features and treatment outcomes of children with Hodgkin's Lymphoma treated with different chemotherapy protocols at a tertiary care center in Pakistan.
Mehreen A; Wali RM; Sindhu II; Asad M; Ria S
J Pak Med Assoc; 2019 Sep; 69(9):1266-1272. PubMed ID: 31511710
[TBL] [Abstract][Full Text] [Related]
19. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor.
Merdin A; Çakar MK; Dal MS; Mert D; Yıldız J; Başçı S; Bakırtaş M; Darçın T; Şahin D; Ulu BU; Yiğenoğlu TN; Batgi H; Tetik A; İskender D; Altuntaş F
J Oncol Pharm Pract; 2020 Jun; 26(4):929-932. PubMed ID: 31822199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
